MARKET

ADXS

ADXS

Advaxis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4690
-0.0502
-9.67%
After Hours: 0.4700 +0.001 +0.21% 19:07 04/16 EDT
OPEN
0.4941
PREV CLOSE
0.5192
HIGH
0.5000
LOW
0.4620
VOLUME
9.11M
TURNOVER
--
52 WEEK HIGH
1.570
52 WEEK LOW
0.2639
MARKET CAP
64.27M
P/E (TTM)
-1.3855
1D
5D
1M
3M
1Y
5Y
8-K: Advaxis, Inc.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
Advaxis Saturday Morning Highlighted Presentation Of Translational Biomarker Data From Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial At American Association For Cancer Research Meeting
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Precision for Medicine, a specialized services company supporting
Benzinga · 5d ago
Advaxis proposes $20M registered direct offering
Advaxis (ADXS) has entered into definitive agreements with two healthcare-focused, institutional investors for the purchase of shares and warrants, with a $20M registered direct offering priced at-the-market.The agreement is for the purchase
Seekingalpha · 5d ago
Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
PRINCETON, Apr 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- PRINCETON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the "Company"), a...
GlobeNewswire · 5d ago
Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting
Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade Assay enables determination of PD-1 expression independent of PD-1 receptor status, accounting fo...
GlobeNewswire · 04/10 13:31
Human Papillomavirus Protein E7 Market: Global Industry Trends, Share, Size, Growth, Industry Statistics, Opportunity and Forecast 2021-2027
Apr 09, 2021 (Market Stats News via COMTEX) -- The latest report as Human Papillomavirus Protein E7 Market acknowledges Size, Application Segment, Type,...
Market Stats News · 04/09 06:30
COVID-19 Pandemic Effect and Impact Analysis on Prostate Specific Antigen Market by 2027
Market Insight Reports · 04/07 10:29
Advaxis to fund earl-stage ADXS-504 study for prostate cancer
Advaxis (ADXS) announces an agreement with Columbia University Irving Medical Center to fund a Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer.The study, expected to
Seekingalpha · 04/05 12:43
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADXS. Analyze the recent business situations of Advaxis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADXS stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 66
Institutional Holdings: 11.64M
% Owned: 8.50%
Shares Outstanding: 137.04M
TypeInstitutionsShares
Increased
9
3.28M
New
11
1.07M
Decreased
5
146.24K
Sold Out
2
195.54K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Non-Executive Chairman/Independent Director
David Sidransky
President/Chief Executive Officer/Chief Financial Officer/Director
Kenneth Berlin
Non-Executive Vice Chairman/Independent Director
James Patton
Executive Vice President
Andres Gutierrez
Chief Accounting Officer/Vice President - Finance
Igor Gitelman
Independent Director
Roni Appel
Independent Director
Richard Berman
Independent Director
Richard Schwalm
Independent Director
Samir Khleif
No Data
About ADXS
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Webull offers kinds of Advaxis, Inc. stock information, including NASDAQ:ADXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADXS stock methods without spending real money on the virtual paper trading platform.